Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
Sponsor: Universität Münster
A PHASE2 clinical study on Brain Tumor, Pediatric, this trial is completed. The trial is conducted by Universität Münster and has accumulated 8 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Dec 2024 — Jan 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Dec 2022 — Jan 2024 [monthly]
Recruiting PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Mar 2021 — Jun 2022 [monthly]
Recruiting PHASE2
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Universität Münster
- medac GmbH
- photonamic GmbH & Co. KG
For direct contact, visit the study record on ClinicalTrials.gov .